甲状腺球蛋白在分化型甲状腺癌诊治中的应用  

The clinical application of thyroglobulin in differentiated thyroid carcinoma

作　　者：陈思涵 汪君瑶 程歆琦[3] 陈立波 Chen Sihan;Wang Junyao;Cheng Xinqi;Chen Libo(Medical College of Yanbian University,Yanbian 133002,China;Department of Nuclear Medicine,Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200233,China;Department of Nuclear Medicine,Peking Union Medical College Hospital,Beijing 100005,China)

机构地区：[1]延边大学医学院,延边133002 [2]上海交通大学医学院附属第六人民医院核医学科,上海200233 [3]北京协和医院核医学科,北京100005

出　　处：《中华转移性肿瘤杂志》2024年第2期165-168,共4页Chinese Journal of Metastatic Cancer

基　　金：国家自然科学基金(82171981)。

摘　　要：甲状腺球蛋白是放射性碘残甲消融后分化型甲状腺癌的特异性肿瘤标志物。甲状腺球蛋白在分化型甲状腺癌的诊断、复发危险度分层明确131I治疗指征、疗效和肿瘤分化程度评价等临床应用中具有多元价值。本文就甲状腺球蛋白在分化型甲状腺癌诊治中的应用进行综述。Thyroglobulin represents a specific tumor marker for differentiated thyroid carcinoma post residual thyroid ablation with radioactive iodine.Multiple thyroglobulin measurements play vital roles in diagnosis,recurrence risk stratification,defining indication of 131I therapy,and evaluating both therapeutic efficacy and tumor differentiation status.This review highlights the clinical applications of thyroglobulin in differentiated thyroid carcinoma.

关 键 词：甲状腺球蛋白 分化型甲状腺癌 病理诊断 复发危险分层 疗效评价 

分 类 号：R736.1[医药卫生—肿瘤]